Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo in Patients With Essential Hypertension

NCT00219128 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo in Patients With Essential Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
June 30, 2005
Enrollment
671 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension